NASDAQ:CNSY Plus Therapeutics (CNSY) Stock Price, News & Analysis $2.94 +0.23 (+8.49%) Closing price 09/2/2026 04:00 PM EasternExtended Trading$2.86 -0.08 (-2.59%) As of 08:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsSEC Filings About Plus Therapeutics Stock (NASDAQ:CNSY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$2.74▼$2.9450-Day Range N/A52-Week Range$2.62▼$23.42Volume60,663 shsAverage Volume74,359 shsMarket Capitalization$22.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue. Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics is advancing 186RNL through clinical development and has not established a portfolio of marketed products. Based in Austin, Texas, Plus Therapeutics conducts its development activities primarily through clinical research in the United States. The company is led by Marc H. Hedrick, M.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCNSY MarketRank™: Plus Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingPlus Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPlus Therapeutics has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.44% of the float of Plus Therapeutics has been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 7.82.Change versus previous monthShort interest in Plus Therapeutics has recently decreased by 0.98%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Plus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for CNSY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of Plus Therapeutics is held by insiders.Percentage Held by Institutions3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive CNSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNSY Stock News HeadlinesCerenome Launches New Corporate Identity as Integrated CNS Oncology CompanyAugust 27, 2026 | markets.businessinsider.comCerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business LinesAugust 20, 2026 | globenewswire.comSee More Headlines CNSY Stock Analysis - Frequently Asked Questions How have CNSY shares performed this year? Plus Therapeutics' stock was trading at $3.91 on August 5, 2026. Since then, CNSY shares have decreased by 24.8% and is now trading at $2.94. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:CNSY) posted its earnings results on Friday, August, 14th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.35. Plus Therapeutics had a negative trailing twelve-month return on equity of 394.17% and a negative net margin of 620.70%. How do I buy shares of Plus Therapeutics? Shares of CNSY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2026Today9/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CNSY's financial health is in the Yellow zone, according to TradeSmith. CNSY has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CNSY CIK1095981 Webplustherapeutics.com Phone(737) 255-7194Fax858-450-4335Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.39 million Net Margins-620.70% Pretax Margin-620.70% Return on Equity-394.17% Return on Assets-151.36% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio0.65 Sales & Book Value Annual Sales$5.21 million Price / Sales4.28 Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book4.08Miscellaneous Outstanding Shares7,590,000Free Float7,400,000Market Cap$22.31 million OptionableN/A Beta1.39 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CNSY) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSY Stock Alerts